Spyridon Sideris

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes et al. · European Urology · 2014 · 258 citations · Full text

Medicine, Oncology, Urology +17

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Clinical impact of ⁶⁸ Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach

Simone Albisinni, Carlos Artigas, Fouad Aoun et al. · British Journal of Urology · 2016 · 112 citations

Medicine, Nuclear Medicine, Oncology +17

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

Mateus Crespo, Guus van Dalum, Roberta Ferraldeschi et al. · British Journal of Cancer · 2015 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

Pasquale Rescigno, David Lorente, Diletta Bianchini et al. · European Urology · 2016 · 70 citations · Full text

Medicine, Oncology, Urology +16